Department of Neuroscience, Monash University, Level 6 Alfred Centre, 99 Commercial Rd, 3004 Melbourne, Australia.
Department of Physiology, Anatomy, and Microbiology, La Trobe University, Science Drive, Bundoora 3086, Australia.
Exp Neurol. 2021 Jul;341:113698. doi: 10.1016/j.expneurol.2021.113698. Epub 2021 Mar 13.
There is a widely recognized need for blood biomarkers to assist clinical decisions surrounding mild traumatic brain injury (mTBI). Serum neurofilament light (NfL), an indicator of neuroaxonal damage, is one such candidate, with early mTBI clinical investigations demonstrating significant promise. To facilitate the translation of pre-clinical mTBI findings, clinically relevant outcomes should be integrated into animal studies wherever possible. Despite this, the temporal profile and potential utility of NfL as a blood biomarker in pre-clinical mTBI is poorly understood. Here, we quantified serum NfL at 2-h, 1-, 3-, 7- and 14-days following mTBI in rats and compared these to pre-injury levels. We also investigated cumulative effects of repeat-mTBI by delivering 0, 1 or 5 mTBIs separated by 24 h. Sensorimotor performance was evaluated with the beam task at 1- and 4-h after mTBI, and serum was collected 1-day after the final procedure. We found that serum NfL levels were substantially elevated at all acute and sub-acute time-points after a single-mTBI, peaked at 1-day, and remained elevated 14-days post-injury. An mTBI dose-dependent effect on serum NfL levels was also observed, with substantially higher NfL levels found at 1-day post repeat-mTBI when compared to single-mTBI and sham-injured rats. Furthermore, NfL levels were found to be greatest in rats with the highest degree of sensorimotor impairment. In conclusion, these findings have described the temporal profile of serum NfL elevations following a single-mTBI in rats, and indicate a profile with some similarities and differences to that seen in the clinical condition. Moreover, we found that serum NfL levels were potentiated by repeat-mTBI, and that this biomarker may have utility as an indicator of injury severity. As such, future pre-clinical TBI studies may benefit from incorporating measures of serum NfL as an objective injury outcome.
人们普遍认识到需要血液生物标志物来辅助轻度创伤性脑损伤(mTBI)的临床决策。血清神经丝轻链(NfL)是一种神经轴突损伤的标志物,就是这样一种候选物,早期 mTBI 临床研究显示出了巨大的应用前景。为了促进临床前 mTBI 研究结果的转化,应尽可能将临床相关的结局纳入动物研究中。尽管如此,NfL 作为一种血液生物标志物在临床前 mTBI 中的时间特征和潜在应用仍知之甚少。在这里,我们在 mTBI 后 2 小时、1 天、3 天、7 天和 14 天定量检测大鼠血清 NfL,并将其与损伤前水平进行比较。我们还通过 24 小时的间隔重复进行 0、1 或 5 次 mTBI ,研究了重复 mTBI 的累积效应。在 mTBI 后 1 小时和 4 小时使用平衡木任务评估感觉运动性能,并在最后一次手术后 1 天采集血清。我们发现,单次 mTBI 后所有急性和亚急性时间点的血清 NfL 水平均显著升高,在 1 天达到峰值,并在损伤后 14 天仍保持升高。还观察到血清 NfL 水平与 mTBI 剂量呈依赖性,与单次 mTBI 和假损伤大鼠相比,重复 mTBI 后 1 天的 NfL 水平明显更高。此外,在感觉运动障碍最严重的大鼠中,NfL 水平最高。总之,这些发现描述了大鼠单次 mTBI 后血清 NfL 升高的时间特征,并表明其与临床状况有一些相似和不同之处。此外,我们发现重复 mTBI 会增强血清 NfL 水平,并且该生物标志物可能作为损伤严重程度的指标具有一定的应用价值。因此,未来的临床前 TBI 研究可能受益于将血清 NfL 作为客观损伤结局的指标。